VivoSeq
Cardiovascular

Cardiogenic Shock

1

Pipeline Programs↗

8

Active Trials↗

1

Companies Involved↗

Cardiogenic Shock is an early-stage landscape with 1 program across 1 company. The most active players are Abiomed Inc..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Abiomed Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Packed Red Blood Cells

NYU Langone Health

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

20

clinical trials

Completed8 · 40%
Recruiting6 · 30%
Unknown status4 · 20%
Active, not recruiting1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Recruiting·OOttawa Heart Institute Research Corporation·Phase 4·NCT05267886·346 enrolled
Cardiogenic Shock Working Group Registry
Recruiting·TTufts Medical Center·N/A·NCT04682483·5,000 enrolled
Cardiac Power Output in Cardiogenic Shock Patients
Recruiting·UUniversity of Chicago·Phase 1·NCT05700617·5 enrolled
Observational Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Recruiting·AAbiomed Inc.·N/A·NCT06964685·350 enrolled
Comparison of an Individualized Transfusion Strategy to a Conventional Strategy in Patients Undergoing Peripheral Veno-arterial ECMO for Refractory Cardiogenic Shock: a Randomized Controlled Trial - ICONE
Recruiting·UUniversity Hospital, Lille·Phase 1·NCT05699005·236 enrolled
Rapid Impella Support and Escalation Trial
Recruiting·UUniversity Hospital of Cologne·N/A·NCT07655479·115 enrolled
Effect of Early Empagliflozin Initiation in Cardiogenic Shock.
Active, not recruiting·—·N/A·NCT07450417·418 enrolled
Selective C-Reactive Protein Apheresis in Cardiogenic Shock Complicating Acute Myocardial Infarction (CRP-SHOCK Trial)
Not yet recruiting·LLeipzig Heart Science gGmbH·Preclinical·NCT07687017·50 enrolled
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04728932·206 enrolled
Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation
Completed·—·Phase 2·NCT00604331·8 enrolled
Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock
Completed·—·Phase 3·NCT04990349·60 enrolled
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
Completed·—·Phase 4·NCT01367743·58 enrolled
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
Completed·NNiguarda Hospital·Phase 2·NCT02591771·24 enrolled
Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.
Completed·CCarelon Research·Phase 3·NCT00000552
Adrecizumab in Cardiogenic Shock
Completed·DDr. med. Mahir Karakas·Phase 2/3·NCT03989531·150 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)